Biomedical Engineering Reference
In-Depth Information
time,” whereas as PAT is very much concerned with continuous improvement. It is,
however, in combination that they deliver their fullest potential and both support a greater
concept of quality in the twenty-first century.
ACKNOWLEDGMENTS
The authors would particularly like to thank Dr. Duane Bonam of Amgen and Dr. Moheb
Nasr of the FDA for permission to use figures from their presentations at IFPAC and Drs
Chris Watts and Ali Afn
an, both from the FDA, for reviewing this chapter.
REFERENCES
[1] Watts DC, Clark JE. Driving the future of pharmaceutical quality. J Process Anal Technol
2006;3(6):6-9.
[2] PAT: A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality
Assurance, September. 2004. http://www.fda.gov.cder/guidance/6419fnl.pdf.
[3] Pharmaceutical cGMPs for the 21st Century: ARisk-Based Approach, 2004. http://www.fda.
gov/cder/gmp/gmp2004/CGMP%20report%20final04.pdf.
[4] Challenge and Opportunity on the Critical Path to New Medical Products, March, 2004.
http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
[5] Pharmaceutical Development: Q8. http://www.ich.org/LOB/media/MEDIA1707.pdf.
[6] Pharmaceutical Development: Annex to Q8. http://www.ich.org/LOB/media/MEDIA4349.pdf.
[7] Pharmaceutical Risk Management: Q9. http://www.ich.org/LOB/media/MEDIA1957.pdf.
[8] Pharmaceutical Quality System: Q10. http://www.ich.org/LOB/media/MEDIA3917.pdf.
[9] EMEA PAT Home Page. http://www.emea.europa.eu/Inspections/PAThome.html.
[10] Reflection Paper. Chemical, Pharmaceutical and Biological Information to be Included in
Dossiers When Process Analytical Technology (PAT) is Employed, 2006. http://www.emea.
europa.eu/Inspections/docs/PATGuidance.pdf.
[11] ASTM E55 Committee Scope. http://www.astm.org/COMMIT/SCOPES/E55.htm.
[12] Simmons S. The future direction of ASTM E55 Committee on manufacture of pharmaceu-
tical products. Eur Pharm Rev 2007;12(6):71-76.
[13] The National Technology Transfer and Advancement Act of 1995, 1995. http://www.tricare.
osd.mil/jmis/download/PublicLaw104_113NationalTechnologyTransfer.pdf.
[14] Winkle H. Address to ASTM E55 Committee, 2005. http://www.astm.org/COMMIT/
E55_fda.pdf.
[15] ChewR, PetkoD. Commissioningandqualification: a newASTMstandard:GMPregulations.
Pharm Eng 2007;38-50.
[16] Cohen N. Life sciences: an introduction to process analytical technology. Control Environ
Mag 2004; available at http://www.cemag.us/articles.asp?pid=419.
[17] Macher J, Nickerson J. Pharmaceutical Industry Wastes $50 Billion a Year Due to Inefficient
Manufacturing, 2006. http://msb.georgetown.edu/newsroom/news/archive/2006/10/pharma-
ceutical_industry_wastes_/.
